Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00290927
Status:
COMPLETED
Last Update Posted:
2009-08-26
First Post:
2006-02-10
Brief Title:
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents OHA OHA Therapy Controlled Open Randomized Parallel Group Comparative Superiority 16-week Multinational Multicenter Study
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy
To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy
To evaluate the safety of HMR1964
To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy
To evaluate the safety of HMR1964
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None